Ignite Creation Date:
2024-07-17 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06462014
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-05-23
Brief Title:
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Description of Relugolix Use in Patients With Prostate Cancer An Analysis of National Veterans Affairs Health Care Network Data
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Detailed Description:
Prostate cancer PC is the most common cancer and the second leading cause of cancer death among men in the United States Androgen deprivation therapy ADT such as injectable luteinizing hormone-releasing hormone LHRH agonists eg leuprolide is the standard of care for PC patients ADT treatment can suppress testosterone level to castrate level and delay the progression of the disease
Relugolix is a recently approved oral GnRH antagonist While the introduction of relugolix has offered a unique opportunity for patients with PC its vital to understand how it is being used in real-world
Relugolix is a recently approved oral GnRH antagonist While the introduction of relugolix has offered a unique opportunity for patients with PC its vital to understand how it is being used in real-world
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VHA Study | OTHER | None | None |